George H. Talbot

George H. Talbot publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where George H. Talbot sits on this spectrum.

George H. Talbot D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where George H. Talbot sits on this spectrum.

Best Publications

• Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America

  Helen W. Boucher;George H. Talbot;John S. Bradley;John S. Bradley;John E. Edwards;John E. Edwards

  7288
  Citations

• Bad Bugs Need Drugs: An Update on the Development Pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America

  George H. Talbot;John Bradley;John Bradley;John E. Edwards;David Gilbert

  1541
  Citations

• 10 × '20 Progress—Development of New Drugs Active Against Gram-Negative Bacilli: An Update From the Infectious Diseases Society of America

  Helen W. Boucher;George H. Talbot;Daniel K. Benjamin;Daniel K. Benjamin;John Bradley;John Bradley

  876
  Citations

• Once-weekly dalbavancin versus daily conventional therapy for skin infection.

  Helen W Boucher;Mark Wilcox;George H Talbot;Sailaja Puttagunta

  530
  Citations

• Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection.

  G. Ralph Corey;Mark Wilcox;George H. Talbot;H. David Friedland

  326
  Citations

• The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium

  R. C. Moellering;P. K. Linden;J. Reinhardt;E. A. Blumberg

  297
  Citations

• Integrated Analysis of FOCUS 1 and FOCUS 2: Randomized, Doubled-Blinded, Multicenter Phase 3 Trials of the Efficacy and Safety of Ceftaroline Fosamil versus Ceftriaxone in Patients with Community-Acquired Pneumonia

  Thomas M. File;Thomas M. File;Donald E. Low;Donald E. Low;Paul B. Eckburg;George H. Talbot

  252
  Citations

• CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections

  Mark H. Wilcox;G. Ralph Corey;George H. Talbot;Dirk Thye

  219
  Citations

• FOCUS 1: A randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia

  Thomas M. File;Donald E. Low;Paul B. Eckburg;George H. Talbot

  214
  Citations

• FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia

  Donald E. Low;Thomas M. File;Paul B. Eckburg;George H. Talbot

  213
  Citations

• Phase 2 Study of Ceftaroline versus Standard Therapy in Treatment of Complicated Skin and Skin Structure Infections

  Unknown

  211
  Citations

• In Vitro Profiling of Ceftaroline against a Collection of Recent Bacterial Clinical Isolates from across the United States

  Yigong Ge;Donald Biek;George H. Talbot;Daniel F. Sahm

  203
  Citations

• Invasive Aspergillus Rhinosinusitis in Patients with Acute Leukemia

  Unknown

  196
  Citations

• Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae.

  James A McKinnell;Jamie P Dwyer;George H Talbot;Lynn E Connolly

  192
  Citations

• Role of fiberoptic bronchoscopy in the diagnosis of invasive pulmonary aspergillosis in patients with acute leukemia

  Steven M. Albelda;George H. Talbot;Stanton L. Gerson;Wallace T. Miller

  181
  Citations

• CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.

  Unknown

  169
  Citations

• Pulmonary cavitation and massive hemoptysis in invasive pulmonary aspergillosis. Influence of bone marrow recovery in patients with acute leukemia.

  S M Albelda;G H Talbot;S L Gerson;W T Miller

  168
  Citations

• Risk factors for amphotericin B-associated nephrotoxicity

  Melanie A. Fisher;George H. Talbot;George H. Talbot;Greg Maislin;Greg Maislin;Bernadette P. McKeon;Bernadette P. McKeon

  164
  Citations

• Invasive pulmonary aspergillosis and acute leukemia. Limitations in the diagnostic utility of the air crescent sign.

  W. B. Gefter;S. M. Albelda;G. H. Talbot;Stanton L Gerson

  160
  Citations

• The Infectious Diseases Society of America’s 10 × ’20 Initiative (10 New Systemic Antibacterial Agents US Food and Drug Administration Approved by 2020): Is 20 × ’20 a Possibility?

  George H Talbot;Amanda Jezek;Barbara E Murray;Ronald N Jones

  136
  Citations